Trials / Active Not Recruiting
Active Not RecruitingNCT06254274
A Study of RAY1225 in Participants With Type 2 Diabetes
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Safety, Tolerability, and Efficacy of RAY1225 in Participants With Type 2 Diabetes
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 210 (actual)
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to learn more about the Tolerability of RAY1225 in participants with type 2 diabetes mellitus. The study will also explore the efficacy of RAY1225. The study will last about six months for each participant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RAY1225 | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2024-02-26
- Primary completion
- 2025-12-20
- Completion
- 2025-12-20
- First posted
- 2024-02-12
- Last updated
- 2025-08-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06254274. Inclusion in this directory is not an endorsement.